Sign in
Not yet recruitingPhase 2

GA001 Injection in Retinitis Pigmentosa

Key facts

Who runs it
GenAns Biotechnology Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
12 people, planned
Starts
1 Apr 2027
Expected to end
25 Nov 2031
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • GA001
  • Sham injection
Record updated
17 November 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male or female participants aged 18 to 70 years
  • Clinical diagnosis of advanced retinitis pigmentosa (RP)
  • Best corrected visual acuity at or below the protocol-defined threshold in the study eye
  • Ability to understand and sign informed consent (and assent, when applicable)
  • Laboratory test results are within the protocol-defined threshold range

Who cannot take part

  • Presence of other ocular conditions that could interfere with study assessments
  • History of significant ocular surgery in the study eye within a protocol-defined period
  • Active ocular infection or inflammation
  • Clinically significant systemic disease that could increase study risk or interfere with assessments
  • Positive screening for clinically significant infectious diseases, as defined in the protocol
  • Any condition that, in the investigator's judgment, would make the participant unsuitable for study participation
  • Pregnant or breastfeeding individuals

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.

The 2 groups in the trial

  • GA001Treatment being tested
  • Sham InjectionSham treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Study to Evaluate the Safety and Efficacy of GA001 Injection in Patients With Retinitis Pigmentosa
Criteria questions
Built from NCT07943312, who can take part
Record updated
17 November 2026